The downregulation of SASH1 expression promotes breast cancer occurrence and invasion accompanied by the activation of PI3K-Akt-mTOR signaling pathway

被引:0
|
作者
Shu Li [1 ]
Yan Su [2 ]
Jun Tian [1 ]
Ke Wang [2 ]
Xiaotong Wang [5 ]
Lin Ding [5 ]
Chunli Li [3 ]
机构
[1] Women and Children’s Hospital of Chongqing Medical University,Department of Clinical Laboratory
[2] Chongqing Health Center for Women and Children,Department of Clinical Laboratory
[3] Women and Children’s Hospital of Chongqing Medical University,Department of Obstetrics and Gynecology
[4] Chongqing Health Center for Women and Children,Department of Obstetrics and Gynecology
[5] Yongchuan People’s Hospital of Chongqing,Department of Clinical Laboratory
关键词
SASH1; PI3K; Akt; mTOR; Breast cancer; Prognosis;
D O I
10.1038/s41598-024-72562-1
中图分类号
学科分类号
摘要
SASH1 (SAM and SH3 domain containing 1) has been increasingly reported as a tumor suppressor gene. However, there is limited research on the role of SASH1 in breast cancer. This manuscript aims to investigate the mechanism of SASH1 in the occurrence, development, and prognosis of breast cancer. Firstly, we obtained RNA-sequencing data of the tumors from the Genomic Data Commons data portal website, along with the corresponding clinical information of patients. Pan-cancer analysis was performed to analyze the expression of SASH1 across all tumors. Univariate Cox regression analysis was used to assess the correlation between SASH1 expression and the prognosis of breast cancer patients. Then, immunohistochemistry was utilized to evaluate the expression levels of SASH1, p-Akt, p-PI3K, and p-mTOR in breast cancer tissue. Finally, a cell assay was employed to analyze the impact of SASH1 on the proliferation and invasion of breast cancer cells (MDA-MB-231). The results revealed that SASH1 expression is decreased in BRCA, LUSC, LUAD, CESC, ESCA, and COAD. Meta-analysis also found that SASH1 is downregulated in most tumor tissues, and the expression level of SASH1 in breast cancer was significantly lower than that in the control group (OR = 0.14, 95% CI = 0.08–0.25; P < 0.001). Further experimental validation showed that SASH1 expression is significantly downregulated in breast cancer tissue (38.33%, 23/60), and the overexpression of SASH1 can inhibit the proliferation and invasion of breast cancer cells accompanied by the suppression of PI3K-Akt-mTOR signaling pathway. Additionally, SASH1 overexpression can improve OS and RFS of breast cancer patients.
引用
收藏
相关论文
共 50 条
  • [21] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [22] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [24] PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells
    Kaarbo, Mari
    Mikkelsen, Oyvind Loveseter
    Malerod, Lene
    Qu, Su
    Lobert, Viola H.
    Akgul, Gulcan
    Halvorsen, Thomas
    Maelandsmo, Gunhild M.
    Saatcioglu, Fahri
    CELLULAR ONCOLOGY, 2010, 32 (1-2) : 11 - 27
  • [25] Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
    Tewari, Devesh
    Patni, Pooja
    Bishayee, Anusha
    Sah, Archana N.
    Bishayee, Anupam
    SEMINARS IN CANCER BIOLOGY, 2022, 80 : 1 - 17
  • [26] Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer
    Meuten, Travis K.
    Dean, Gregg A.
    Thamm, Douglas H.
    VETERINARY PATHOLOGY, 2024, 61 (03) : 339 - 356
  • [27] Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk
    Chen, Meng
    Cassidy, Adrian
    Gu, Jian
    Delclos, George L.
    Zhen, Fan
    Yang, Hushan
    Hildebrandt, Michelle A. T.
    Lin, Jie
    Ye, Yuanqing
    Chamberlain, Robert M.
    Dinney, Colin P.
    Wu, Xifeng
    CARCINOGENESIS, 2009, 30 (12) : 2047 - 2052
  • [28] The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer
    Nicolini, Andrea
    Ferrari, Paola
    Kotlarova, Lucie
    Rossi, Giuseppe
    Biava, Pier M.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2015, 16 (09) : 804 - 815
  • [29] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
  • [30] Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway
    Li, Gang
    Xu, Dongxin
    Sun, Jinju
    Zhao, Shiyun
    Zheng, Dan
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (11): : 1337 - 1345